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18F-FDGAbstract Objective: To assess the use of positron emission tomography (PET)/computed tomog-
raphy (CT) in patients with suspected ovarian cancer recurrence and describe the distribution of
metastasis.
Patients and methods: This study included (39) patients suspected to have recurrent ovarian malig-
nancy. This suspicion was either clinically, radiologically or due to raised CA-125 levels. All
patients underwent 18F-FDG PET/CT, surgery was performed within 8 weeks of imaging studies.
Surgical and/or histopathological examinations were available in 31 patients, and clinical, radiolog-
ical and CA 125 serum level follow up in 8 patients.
Results: The overall lesion-based sensitivity, speciﬁcity, and accuracy of PET/CT for revealing
recurrent ovarian carcinoma were 90%, 98% and 97%, respectively. The patient – based sensitivity,
speciﬁcity, and accuracy of PET/CT were 97%, 75% and 95%, respectively.
Conclusion: 18F-FDG PET/CT is a useful tool for evaluating the recurrence of ovarian cancer
after ﬁrst-line therapy in patients with a high risk of relapse, equivocal radiologic ﬁndings, increased
or normal levels of serum CA-125. It can more accurately diagnose and localize recurrence, hence
decreasing the rate of second look surgery and changing treatment plan.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine.Open access under CC BY-NC-ND license.1. Introduction
Ovarian cancer is the 5th cancer for both incidence and death
among women (1). Symptoms of ovarian cancer are nonspe-
ciﬁc, and the majority of women have advanced disease at pre-
sentation (2).
Despite high response after initial treatment (cytoreductive
surgery and adjuvant chemotherapy), 20–30% of patients with
early-stage disease and up to 75% of patients with advanced
disease present with recurrence within two years (3,4).
Fig. 1 Lymph node metastasis in a 55 year-old female patient with ovarian cancer, histopathology showed bilateral adnexal papillary
serous carcinoma G2 with omental deposits and focal uterine serosal surface involvement underwent TAH & BSO with infracolic
omentectomy followed by chemotherapy. (a, e, and h) Axial contrast-enhanced CT, (b, f, and i) FDG PET, (c, g, and j) fused PET/CT,
and (d and k) coronal fused PET/CT images show multiple metabolically active FDG seen in porta hepatis (a–d), right inguinal lymph
nodes (e–g), right cervical (h–k), and external iliac lymph nodes (k). The porta hepatis nodes are the largest measuring 3.5 · 2 cm in
diameters with max.SUV  13.7, ﬁndings indicative of metastatic nodal disease.
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ture therapeutic strategies. It aims either to cure or to prolong
disease-free survival and to improve the quality of life. Metas-
tases from ovarian cancer are primarily peritoneal rather than
parenchymal in location. Therefore, they usually occur on the
surfaces of the viscera. These tumor implants can be very small
with attenuation similar to surrounding viscera at computed
tomography (CT), which makes their detection challenging
(5,6).
A number of approaches are used to detect recurrent met-
astatic lesions after initial surgery and chemotherapy for ovar-
ian cancer. These include physical examination, serial
measurement of serum cancer antigen-125 levels, anatomic
imaging, including CT and magnetic resonance (MR) imaging,
and positron emission tomography (PET) (6).
Serial measurement of the level of the tumor marker CA-
125 is routinely used to monitor the response of ovarian cancer
to treatment and as a sensitive marker for tumor recurrence.
However, it does not provide information concerning the size
and distribution of the lesions (4,7,8).
Use of serum CA-125 assay, physical examination and ana-
tomic imaging to evaluate patients with ovarian cancer is asso-
ciated with limited success, and currently there is no agreement
on which type of follow-up examination should be used or
when it should be employed. Also, surgical exploration of
the abdomen is frequently used to detect recurrence, however,this method is an invasive procedure and recurrence may also
be observed in the patients with negative exploration (9,10).
Integrated positron emission tomography (PET/CT) pro-
vides combined metabolic and anatomic information about
cancer recurrence and, therefore, it is able to increase lesion
detection by determining the exact location of disease with
capability to survey the whole body (7). Several studies have
examined the performance of PET/CT scanning in patients
with recurrent ovarian cancer (11–13).
The aim of the present study was to assess the value of pos-
itron emission tomography (PET/CT) in diagnosis of ovarian
cancer recurrence and in metastatic work up.2. Patients and methods
2.1. Study cohort
This study was conducted at Radiology and Obstetric & Gyne-
cology Departments, Zagazig University Hospitals, Egypt, be-
tween February 2010 and January 2013. The study was
approved by the local Ethics committee. Informed consent
was obtained from all patients.
This study included (39) patients suspected to have recur-
rent ovarian malignancy. This suspicion was either clinically
or due to raised CA-125 levels or alterations detected on
Fig 1. (continued)
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patients for whom a second-look surgery was performed, sur-
gery was done within 8 weeks of imaging studies. The median
period between PET/CT and exploratory surgery was
3.6 weeks (range, 1.0–12.6 weeks).
2.2. Imaging technique
All CT and PET scans in our study were performed in the
same sitting with a PET/CT scanner (Biograph, Siemens) sys-
tem with 64-slice multi-detector CT. Scans were acquired from
skull base to mid-thigh level. The CT scan component was ob-
tained before the PET component by using the following
parameters: 80–100 mA, 140 kV, 5 mm collimation, 0.5 s rota-
tion time; and pitch = 0.984. Patients were positioned supine
with arms up whenever tolerated to avoid artifact, they were
allowed to maintain normal respiration during scanning. The
I.V. contrast medium (2 ml/kg, 5 ml/s of nonionic contrastmedia) was administered immediately before CT scan. For
FDG PET–CT scan, patients were required to fast for 6 h
prior to scan. Diabetic patients were asked to fast for 4 h be-
fore the study, and could eat and take their insulin just prior
to fasting. Blood glucose levels were obtained in patients with
a history of diabetes mellitus, and scanning was not performed
when serum glucose levels exceeded 200 mg/100 ml. Twenty
milligrams of furosemide was additionally injected intrave-
nously to limit the radiation exposure of the urinary bladder
and to increase the diagnostic accuracy for the urinary tract.
PET/CT was done after I.V. administration of approximately
5 MBq/kg body weight of FDG (up to 555 MBq = 20 mCi).
The patient was then instructed to rest in the supine position
for 45 min to avoid non-speciﬁc muscular uptake. Subse-
quently, PET data were acquired in at 5–7 bed positions for
5 min per each bed position. Data obtained from the CT acqui-
sition were used for attenuation correction of 18FDG-PET
emission data. 18FDG-PET images were reconstructed with
Table 1 Histologic types of ovarian cancer included in the
916 G.K. Gouhar et al.a 4.5 mm thickness. 18FDG-PET, CT and fused 18FDG-PET/
CT images were reviewed on the dedicated workstation.Table 2 Patient distribution according to FIGO staging.






Histologic type No. Percent
Serous papillary carcinoma 34/39 87.2
Clear cell adenocarcinoma 3/39 7.7
Undiﬀerentiated carcinoma 2/39 5.12.3. Image analysis
Images were reviewed by the radiologist who was blinded as to
the results of serum CA-125 testing and of other imaging
modalities. Axial sections and multiplanar reconstructions of
CT, PET and fused PET/CT images were analyzed for recur-
rent ovarian carcinoma. The evaluation of each focal radio-
tracer uptake was qualitative and quantitative. For
qualitative evaluation any foci of FDG uptake that was in-
creased relative to the background and were not located in
areas of physiologically increased uptake were considered to
be positive for recurrent lesions on PET/CT imaging. Quanti-
tative evaluation of areas of increased activity can be per-
formed on attenuation-corrected scans. The maximum
standardized uptake value (SUV max) of a lesion is calculated
to determine if the lesion is more likely to be benign or malig-
nant and is deﬁned as follows:
SUV max = (dose in tissue/injected dose) · patient weight,
where dose in tissue is in millicuries per milliliter, injected dose
is in millicuries, and patient weight in grams.
Six regions were evaluated for the purposes of analysis: pel-
vic local recurrence, peritoneum, pelvic lymph nodes, para-
aortic lymph nodes, distant lymph nodes, and metastatic
disease.
2.4. Standard of reference
In the examined patients, ﬁnal diagnosis (whether there is
recurrence or not) was made either histologically (n= 31)
[after surgery (n= 23), biopsy or mediastinoscopy (n= 8)]
obtained within 4 weeks of FDG-PET/CT, or by follow up
of response to second-line chemotherapy through change in
serum CA-125 levels and radiological follow-up for a mean
period of 6 months (5–7 months) (n= 8).
Surgery was performed by dedicated gynecologic oncology
surgical teams, at exploratory surgery, tumor tissue locations
evaluated by imaging were checked, and Surgeons’ detailed in-
tra operative notes and pathology reports were used as the
standards of reference.
In patients treated with second-line chemotherapy with
high serum CA-125 levels and a histological conﬁrmation
was not available the PET/CT scan was considered true posi-
tive when the tumor marker returns to normal at the end of
chemotherapy with associated improvement of clinical status
and regression of the soft tissue mass on radiological follow-
up.Table 3 Diagnostic results of PET/CT of relapse in the




Positive 34 1 35
Negative 1 3 4
Total 35 4 392.5. Statistical analysis
Data were analyzed using specialized software (SPSS for Win-
dows v10). The sensitivities, speciﬁcities, and accuracies for tu-
mor detection with PET–CT were compared to intraoperative
ﬁndings and results at histological analysis after surgery, or
clinical, and imaging follow-up as standards of reference.
Both patient-based and lesion-based analyses were con-
ducted. The probability (p value) was considered signiﬁcant
when p< 0.05.3. Results
A total of 39 patients, in whom recurrent ovarian cancer was
suspected, were subjected to PET/CT. The mean age of pa-
tients was 54.8 ± 8.3.
The range of serum CA 125 levels was 4–959 U/ml, with a
mean level of 132 ± 150 U/ml. The threshold level for normal
CA-125 was 30 U/ml.
Thirty-four patients had serous papillary adenocarcinoma,
three patients had clear cell tumor, and two patients had undif-
ferentiated carcinoma (Table 1).
According to FIGO classiﬁcation 79% (31/39) of the pa-
tients, had an advanced ovarian cancer at initial diagnosis;
7.7% (3/39) of the patients were FIGO I, 12.82% (5/39) were
FIGO II, 53.84% (21/39) were FIGO III, and 25.64% (10/39)
were FIGO IV (Table 2).
According to ﬁnal diagnosis 35 patients were positive for
recurrent ovarian cancer, and 4 patients were negative.
Of the 35 positive cases, 23 patients had surgery done for
resection of lesions. In all operated patients, the tumor tissue
was removed and examined histologically. 8 patients had both
distant and pelvic metastasis and were conﬁrmed by biopsy.
While in 4 patients a histological conﬁrmation was not avail-
able and the diagnosis was conﬁrmed by the change in serum
CA-125 levels after second line chemotherapy and radiological
follow-up for at least 5 months.
In all of the four negative cases, diagnosis was conﬁrmed by
the change in serum CA-125 levels after second line chemo-
therapy and radiological follow-up for at least 5 months.
Fig. 2 Para-aortic lymph node metastasis in a 63 year-old female patient with history of right ovarian carcinoma, histopathology
showed papillary serous carcinoma G3 underwent PAN hysterectomy and omentectomy received radio- and chemotherapy. (a) Axial
contrast-enhanced CT, (b) FDG PET, (c) fused PET/CT, and (d) coronal fused PET/CT images show multiple enlarged para-aortic lymph
nodes amalgam is seen encasing the left side of the aorta, measuring 6.6 cm in diameter, demonstrates markedly increased FDG uptake,
with max.SUV  28.4. It is seen entangling the proximal part of left ureter with subsequent moderate hydronephrotic changes, a ﬁnding
indicative of metastatic nodal disease.
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tive in 4/39 patients; 34/35 patients were true-positive cases, 3/
4 true-negative cases, 1/35 false-positive case, and 1/4 false-
negative cases (Table 3).
PET/CT described 73 lesions with suspicion of recurrence
which were: 24 lesions in the pelvis, 5 lesions in the region of
pelvic lymph nodes, 10 lesions in the region of para-aortic
lymph nodes, 22 peritoneal and 12 distant lesions. Representa-
tive cases are shown in (Figs. 1–5).
PET/CT showed full sensitivity, speciﬁcity and accuracy for
local pelvic recurrence and distant organ metastasis (24/24 le-
sions in the lesser pelvis, and 4/4 lesions in the distant organs
metastasis).
In pelvic lymph nodes the sensitivity, speciﬁcity, and accu-
racy of PET-CT were 80%, 99% and 97%, respectively (4/5
true positive, one false positive and one false negative lesion),
while in para-aortic lymph nodes were 78%, 96% and 94%,
respectively (7/9 true positive, three false positive and two false
negative lesions).
In peritoneal metastasis there were 20/26 true positive le-
sions, two false positive and six false negative lesions, corre-
sponding to a sensitivity, speciﬁcity, and accuracy of 77%,
96% and 90%, respectively.In distant lymph node metastasis there were 8/9 true posi-
tive lesions, and one false negative lesion, corresponding to a
sensitivity, speciﬁcity, and accuracy of 89%, 100% and 99%
respectively, P value < 0.0001 (highly signiﬁcant) (Table 4).
The overall lesion-based sensitivity, speciﬁcity, and accu-
racy of PET/CT for revealing recurrent ovarian carcinoma
were 90%, 98% and 97%, respectively. The patient – based
sensitivity, speciﬁcity, and accuracy of PET/CT were 97%,
75% and 95%, respectively (Table 5).
The SUV of FDG in positive cases varied from 3.4 to 28.9,
median 8.4.
4. Discussion
Although ovarian cancer accounts for 3% of all cases of cancer
in females, it has the highest mortality of all gynecological can-
cers, due to advanced stage disease at presentation (1). More-
over, it has a high recurrence rate which is challenging in its
diagnosis (6). Serum CA-125 level is an indicator of activity
in epithelial tumors (14,15). Detection of elevated CA-125 pre-
dicts recurrence in 85% of patients (16). Elevation of CA 125
values can be detected 3–6 months before clinical and radio-
logical ﬁndings (17).
Fig. 3 Peritonal and hepatic metastasis in a 53 year-old female patient, ovarian cancer, histopathology showed serous papillary
cystadenocarcinoma G3 underwent panhysterectomy followed by chemotherapy. (a and d) Axial contrast-enhanced CT, (b and e) FDG
PET, (c and f) fused PET/CT, and (g) coronal fused PET/CT images show multiple innumerable metabolically active FDG avid metastatic
deposits involving the peritoneal reﬂections (a–c), moreover multiple metabolically active FDG avid hypodense hepatic focal lesions (d–f)
distributed all over both hepatic lobes, the largest is seen in segment IV with max.SUV  8.4, ﬁndings indicative of peritoneal and hepatic
metastasis.
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Fig. 4 Mediastinal lymph node metastasis in a 60 year-old female patient with history of ovarian carcinoma, histopathology showed
papillary serous carcinoma G3 underwent PAN hysterectomy, received radio- and chemotherapy. (a) Axial contrast-enhanced CT, (b)
FDG PET, and (c) fused PET/CT fused images show enlarged right hilar lymph node demonstrate markedly increased FDG uptake, with
max.SUV  17.4, ﬁnding suggestive of mediastinal lymph node metastasis.
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pected recurrent tumor. However, 40–60% of patients treated
for ovarian carcinoma, with normal CA 125 levels and nega-
tive clinical ﬁndings for recurrence were proved to have recur-
rence on second look laparotomy (18).
PET-CT is one of the methods used to detect ovarian
cancer recurrence; its metabolic tracer makes it superior to
other methods in lesion detection ability (19). Several studies
have shown that, among patients who are suspected of hav-
ing ovarian cancer recurrence, PET/CT has the greatest util-
ity in those patients with rising or normal CA 125 levels and
negative conventional imaging results (11,20–23). Further-
more, three prospective studies have shown that PET/CT
can help modify patient treatment by accurately describing
the distribution of recurrent ovarian cancer (12,13,24). In
one study (13) on 90 women who were suspected of having
recurrent ovarian cancer, Fulham et al. (13) found that
PET/CT could detect more sites of disease than did CE
CT, and treatment was altered in 60% of patients. Using
FDG PET/CT instead of second look laparotomy was cost
effective in some studies (18).
In our study, a total of 39 patients were subjected to PET/
CT for suspicious recurrent ovarian cancer. At the patient le-
vel, PET/CT scan was positive in 35/39 patients and negativein 4/39 patients. This corresponded to 34/35 true-positive
cases, 3/4 true-negative cases, 1/35 false-positive cases and 1/
4 false-negative cases (Table 3). The patient – based sensitivity,
speciﬁcity, and accuracy of PET/CT were 97%, 75% and 95%,
respectively. The overall lesion-based sensitivity, speciﬁcity,
and accuracy of PET/CT for revealing recurrent ovarian carci-
noma were 90%, 98% and 97%, respectively (Table 5).
These results are concordant with many studies in which
researchers found that accuracy, sensitivity, and speciﬁcity
were 63–100%, 73–100%, and 40–100%, respectively, at the
patient level and 72–96%, 41–78%, and 75–99%, respectively,
at the region level (6,11–13,20–30).
In agreement with Simcock et al. (12), our study showed
that the diagnostic accuracy of PET/CT was higher in clinical
and imaging follow-up group (8 cases), rather than the surgi-
cally and/or biopsy conﬁrmed group (31 cases); this is because
direct visualization of lesions and histopathologic examination
of the multiple biopsies taken at operation is expected to have
more accuracy than clinical and imaging follow-up and, there-
fore, second-look surgery is the most accurate way to deter-
mine the macroscopic and microscopic disease.
In this study, PET–CT showed full sensitivity, speciﬁcity
and accuracy for local pelvic recurrence and distant organ
metastasis. In pelvic lymph nodes the sensitivity, speciﬁcity,
Fig. 5 Recurrent ovarian cancer in a 49 year-old female patient with ovarian carcinoma, histopathology showed bilateral ovarian
granulosa cell carcinoma G2, underwent TAH&BSO, received chemotherapy. (a and d) Axial contrast-enhanced CT, (b and e) FDG PET,
and (c and f) fused PET/CT fused images show multiple conﬂuent soft tissue masses (a–c) are seen posterior and superior to the urinary
bladder and partially entangling the rectum and sigmoid colon, with low grade FDG uptake and max.SUV  4.5. the left lateral rectal (d–
f) wall appears thickened and partially inseparable from the left pelvic component of the fore mentioned mass lesions, ﬁnding suggestive of
local pelvic recurrence.
Table 4 Accuracy measures of PET/CT in lesion localization (Lesion-based).
Localization Number of lesions Sensitivity (%) Speciﬁcity (%) Accuracy (%)
Pelvic recurrence 24 100 100 100
Pelvic lymph node 5 80 99 97
Para-aortic lymph node 10 78 96 94
Peritoneal metastasis 22 77 96 90
Distant lymph node 8 89 100 99
Distant organ metastasis 4 100 100 100
920 G.K. Gouhar et al.and accuracy of PET–CT were 80%, 99% and 97%
respectively, while in distant lymph node metastasis they were
89%, 100% and 99%, respectively. In para-aortic lymph nodesthe sensitivity, speciﬁcity, and accuracy of PET-CT were 78%,
96% and 94% respectively, in peritoneal metastasis they were
77%, 96% and 90%, respectively.
Table 5 Accuracy measures of PET/CT in revealing recurrent
ovarian tumor.
PET/CT Sensitivity (%) Speciﬁcity (%) Accuracy (%)
Lesion-based 90 98 97
Patient-based 97 75 95
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sults are concordant with previous studies (19,21,31) who sta-
ted that there was an excellent correlation between PET–CT
and operative ﬁndings, with excellent sensitivity and speciﬁcity
for all sites except for para-aortic lymph nodes (a sensitivity of
83%), and diffuse peritoneal carcinosis (a sensitivity of 79%)
(31).
However, our results did not agree with those of Sala et al.
(7) who found that PET/CT was most accurate in the detection
of lesions in the peritoneum, while the detection of pelvic local
recurrence, distant (above renal hila) lymph node invasion,
and distant metastases in the liver and spleen was limited. They
stated that most of the cases with false-negative results for liver
and splenic metastases were caused by mislabeling rather than
a failure to visualize an intra organ lesion (7).
There are several pitfalls associated with PET–CT including
the normal physiologic activity in the bowel loops; focal re-
tained activity in the urinary system; FDG uptake within ath-
erosclerotic plaque; and misalignment due to bowel peristalsis,
bladder ﬁlling, or diverticulitis (9,32). Increased 18F-FDG up-
take due to myomatosis has been reported as a possible cause
of false-positive PET scan in the pelvic region, as well as severe
bowel inﬂammation due to post-surgical ﬁbrosis. The false-
negative results occur in ovarian clear-cell carcinoma which
is characterized by a low cellular glucose metabolism in a sim-
ilar manner as already described for renal clear-cell tumours.
False-negative FDG PET/CT results may also occur in pa-
tients with cystic or necrotic lesions or lesions with copious
mucinous collections. Another common cause of false-negative
18F-FDG PET results is related to possible misinterpretation
of focal tracer uptake in difﬁcult anatomical positions such
as the upper abdomen (respiratory artifacts), kidney, urethral
and bladder regions (physiologic urinary activity) (21).
A number of reports have commented on the limited ability
of PET and PET–CT to detect small volume disease-peritoneal
nodules, non enlarged nodes-in patients with suspected recur-
rence (33–35). However, Fulham et al. (2009) experienced dif-
fers and they identiﬁed additional unsuspected sites of disease
in 61 patients. The majority of these patients had nodal or dis-
crete peritoneal lesions but they also identiﬁed 8 patients where
there was diffuse FDG uptake throughout the abdomen con-
sistent with miliary peritoneal involvement. This type of spread
is well recognized in advanced disease (13).
A limitation of our study is that there was no pathological
conﬁrmation of all the sites of abnormal 18FDG uptake. How-
ever, the conﬁrmation of all the sites would not have been eth-
ically accepted for the purpose of validation of PET/CT
ﬁndings.
In conclusion, the results of this study show that 18F-FDG
PET/CT is a useful tool for evaluating recurrence of ovarian
cancer after ﬁrst-line therapy in patients with high risk of re-
lapse, equivocal radiologic ﬁndings, increased or even non-ele-
vated levels of serum Ca125. It can more accurately diagnoseand localize recurrence, hence decreasing the rate of second
look surgery and changing treatment plan.
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